December 14, 2009 (FinancialWire) — XOMA Ltd. (NASDAQ: XOMA), a leader in the discovery and development of therapeutic antibodies, reported results demonstrating the advantages of its monoclonal antibody technologies in the rapid development of a first-in-class multiple antibody product candidate, XOMA 3AB.

XOMA 3AB is designed to neutralize botulinum neurotoxin Type A, which causes paralysis and is a bioterror threat. The results were presented at the 20th Annual International Conference on Antibody Engineering being held December 6 to 10 in San Diego, CA.

A major problem with treating botulism and many infectious diseases is that a single antibody may not be effective in neutralizing a toxin or infectious agent, particularly when multiple strains or subtypes exist. XOMA’s technologies enable it to co-formulate and deliver multiple antibodies in a single injectable solution, which facilitates delivery and has the potential to increase efficacy for infectious and other diseases. XOMA 3AB is comprised of three human antibodies that bind to unique epitopes on the botulinum A toxin, which in composite provide unprecedented potency against the toxin. XOMA is developing XOMA 3AB under existing research contracts with the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health .

This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Department of Health and Human Services under contract numbers HHSN266200600008C and HHSN272200800028C. Contract HHSN272200800028C was awarded in 2008 for a total of $65 million.

Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). Recently issued reports and filings include Bravo Venture Group Inc. (TSX Venture: BVG), Bellway PLC (London Stock Exchange: BWY) (OTC: BLWYF), Chase Corporation (AMEX: CCF), Continental Materials Corp. (AMEX: CUO), Amcon Distributing Company (AMEX: DIT), Eaton Vance Enhanced Equity Income Fund (NYSE: EOI), Majedie Investments PLC (London Stock Exchange: MAJE), Morgan Stanley Income Securities, Inc. (NYSE: ICB), Grainger PLC (London Stock Exchange: GRI) (OTC: GRTGF), Eaton Vance Insured Municipal Bond Fund (AMEX: EIM), PIMCO High Income Fund (NYSE: PHK) and Shaw Communications, Inc. (NYSE: SJR).

FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors by the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/). Recently-presented company financial results calls, earnings calls and/or shareholder meeting webcasts now available include Aastrom Biosciences, Inc. (NASDAQ: ASTM), Methode Electronics, Inc. (NYSE: MEI), White Electronic Designs Corporation (NASDAQ: WEDC), Cantel Medical Corp. (EXCH: CMN), Frequency Electronics Inc. (EXCH: FEIM), Pep Boys-Manny, Moe & Jack (NYSE: PBY) and Xeta Technologies, Inc. (NASDAQ: XETA). Recordings are accessible via the search function at http://infoescrow.net/f/?u=http://www.investorcalendar.com by entering any company’s ticker symbol into the search field.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site  (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.